Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents.

Employees

397

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-07-23	€0.9320	-0.64%	4,657
26-07-22	€0.9380	+0.86%	760
26-07-21	€0.9300	+2.20%	6,223
26-07-20	€0.9100	+2.02%	23,008
26-07-17	€0.8920	-0.89%	1,050

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-07-23 EDT			5-day change	1st Jan Change
0.9320 ^EUR	-0.64%		+3.56%	+56.38%

06-11	Triple update for Biosynex
06-10	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI

Market Cap	17.18M 19.53M 15.96M 14.68M 27.53M 1.89B 28.02M 191M 74.44M 923M 73.33M 71.74M 3.2B	P/E 2024	-0.43x	P/E 2025	-0.19x
Enterprise Value	70.37M 80.01M 65.37M 60.12M 113M 7.75B 115M 782M 305M 3.78B 300M 294M 13.11B	EV / Sales 2024	0.71x	EV / Sales 2025	0.68x
Free-Float	40.35%	Yield 2024 *	-	Yield 2025	-

06-11	Triple update for Biosynex
06-10	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
05-25	Paris climbs on hopes of Middle East de-escalation
05-25	Biosynex announces the divestment of its molecular biology business
05-24	An undisclosed buyer signed a binding offer to acquire Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
05-07	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-06	Biosynex SA Auditor Raises 'Going Concern' Doubt	CI
04-21	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
04-21	Biosynex postpones publication of annual accounts
03-24	Abivax, Ekinops, Sanofi... stocks to watch today in Paris
03-24	Observation period extended for Biosynex
02-06	A Biosynex Subsidiary to Receive $1.8 Million Grant
02-06	Aperam, Société Générale, Stellantis: Key Stocks to Watch Today in Paris

24-10-23	BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY	EQ
23-04-27	Biosynex Completes Acquisition of Chembio Diagnostics, Inc.	AQ
23-04-13	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-03-15	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-01-31	Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement	AQ

Biosynex Stock

Stocks

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Valuation: Biosynex

Chart: Biosynex

Latest news : Biosynex

Press Releases: Biosynex

News in other languages: Biosynex

Quotes and Performance

Course Extremes

Managers and Directors: Biosynex

Latest insider transactions

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

07-22	BIOSYNEX SA: CHIFFRE D’AFFAIRES DU 1er SEMESTRE 2026 : 44,1 M€ - PERSPECTIVES
06-13	Agenda des dividendes et des AG France : GTT, Alten et Exail sur les tablettes
06-11	Bourse : J-1 avant SpaceX, Oracle à la peine, contrat pour Airbus
06-11	Une bonne grosse purge avant SpaceX
06-11	Triple actualité pour Biosynex

1 day	-0.64%
1 week	+3.56%
Current month	+3.33%
1 month	+4.72%
3 months	+11.75%
6 months	+5.91%
Current year	+56.38%

1 week	0.89	0.96
1 month	0.8	1.01
Current year	0.56	1.57
1 year	0.46	1.57
3 years	0.46	11
5 years	0.46	28.78
10 years	0.46	30.38

Manager	Title	Age	Since
Larry Abensur CEO	Chief Executive Officer	71	2015-06-23
Thierry Paper CTO	Chief Tech/Sci/R&D Officer	63	2014-12-31
Oren Bitton PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Thierry Paper BRD	Director/Board Member	63	2015-06-23
Thomas Lamy BRD	Director/Board Member	-	2015-06-23
Larry Abensur CHM	Chairman	71	2015-06-23

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/15/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
2/15/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
2/28/22	Larry Abensur	Buy	Chief Executive Officer	2,000	0.0180%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNEX	-0.64%	+3.56%	-24.53%	-91.11%	19.73M
GUARDANT HEALTH, INC.	-0.36%	-3.10%	+230.47%	+298.83%	19.99B
BIOMÉRIEUX	-1.22%	-5.09%	-43.44%	-27.84%	9.4B
LANTHEUS HOLDINGS, INC.	-0.84%	-1.31%	+41.50%	+18.49%	6.81B
10X GENOMICS, INC.	+2.15%	+8.05%	+252.86%	-19.85%	5.97B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-1.59%	+8.49%	-13.14%	-23.02%	5.62B
ANDON HEALTH CO., LTD.	-10.00%	+9.69%	+88.17%	+110.73%	5.06B
CARIS LIFE SCIENCES, INC.	+1.76%	-5.04%	-47.89%	-	4.35B
DIASORIN S.P.A.	0.00%	-4.24%	-26.67%	-28.44%	4.05B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.68%	-0.86%	-16.61%	-39.76%	2.76B
Average	-1.24%	-1.08%	+44.07%	+22.00%	6.4B
Weighted average by Cap.	-1.06%	-1.91%	+93.71%	+99.23%

	2024	2025
Net sales	101M 115M 93.98M 86.44M 162M 11.14B 165M 1.12B 438M 5.43B 432M 422M 18.85B	95.19M 108M 88.43M 81.34M 153M 10.48B 155M 1.06B 412M 5.11B 406M 398M 17.74B
Net income	-43.33M -49.27M -40.26M -37.02M -69.43M -4.77B -70.68M -481M -188M -2.33B -185M -181M -8.07B	-58.22M -66.2M -54.09M -49.75M -93.29M -6.41B -94.97M -647M -252M -3.13B -249M -243M -10.85B
Net Debt	52.94M 60.19M 49.18M 45.23M 84.82M 5.83B 86.34M 588M 229M 2.84B 226M 221M 9.86B	53.19M 60.48M 49.41M 45.45M 85.23M 5.86B 86.76M 591M 230M 2.86B 227M 222M 9.91B